A NEW breast cancer drug which has been trialled in Scotland will boost survival rates, according to new research.
Survival data from a study into pertuzumab, trade name Perjeta, found the drug reduced the risk of death by 34% in patients with previously untreated advanced HER2-positive breast cancer, a particularly aggressive form of the disease.
We moderate all comments on HeraldScotland on either a pre-moderated or post-moderated basis. If you're a relatively new user then your comments will be reviewed before publication and if we know you well then your comments will be subject to moderation only if other users or the moderators believe you've broken the rules, which are available here.
Moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours. Please be patient if your posts are not approved instantly.
